n engl j med 351;20 www.nejm.org november 11 , 2004 The new england journal of medicine 2050 eurohormonal inhibitors alone or in combination slow the progression of left ventricular dysfunction, retarding the structural remodeling of the left ventricle that characterizes chronic heart failure and reducing the rates of death and complications among patients with heart failure. 1-10 Endothelial dysfunction, impaired bioavailability of nitric oxide, and increased oxidant stress also occur in patients with congestive heart failure and contribute to the remodeling process in experimental and clinical models of heart failure. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Augmentation of nitric oxide may therefore be an alternative or supplemental approach to slow or reverse progressive heart failure. The first Vasodilator Heart Failure Trial (V-HeFT I) 6 demonstrated the benefit of combining the nitric oxide donor isosorbide dinitrate with the antioxidant hydralazine in patients with mild-to-severe heart failure; however, the potential long-term benefit of this therapy in patients treated with neurohormonal inhibitors has not been evaluated.
Differences exist in the prevalence and causation of congestive heart failure and in the associated morbidity and mortality, consistent with population-based variations in the mechanisms of heart failure. [28] [29] [30] Studies have suggested that persons who identify themselves as black may have, on average, a less active renin-angiotensin system 29, 31 and a lower bioavailability of nitric oxide than those selfidentified as white. [32] [33] [34] [35] [36] [37] Retrospective analyses of the databases of previous heart-failure trials 38, 39 strongly suggested that black patients have a clinically significant response to a combination of isosorbide dinitrate and hydralazine. On the basis of these observations, we evaluated the efficacy of a fixed dose of isosorbide dinitrate plus hydralazine in black patients who had New York Heart Association (NYHA) class III or IV heart failure with dilated ventricles and who were receiving background therapy that included neurohormonal blockers.
study design
The African-American Heart Failure Trial (A-HeFT) was a randomized, placebo-controlled, doubleblind trial with patients recruited at 161 centers in the United States. The study protocol was reviewed and approved by the institutional review board at each site. All patients gave written informed consent. Site monitoring, data collection, and data management were performed by Medifacts International, a clinical research organization. Data analysis was performed by independent statisticians and by Virtu Stat. The study sponsor was NitroMed. Independent committees adjudicated all primary and secondary end points, reviewed data on safety, and oversaw the two prespecified interim analyses, which were performed solely to assess the adequacy of the sample size. The manuscript was prepared by the authors and reviewed by the steering committee and the sponsor. The study design has been described previously. 40, 41 inclusion and exclusion criteria Patients 18 years of age or older, self-identified as black (defined as of African descent), who had had NYHA class III or IV heart failure for at least three months were eligible for screening. Patients were required to have been receiving standard therapy for heart failure, as determined to be appropriate by their physicians; such therapy included angiotensin-converting-enzyme inhibitors, angiotensinreceptor blockers, beta-blockers for at least three months before randomization, digoxin, spironolactone, and diuretics. Patients also had to have evidence of left ventricular dysfunction within the six months preceding randomization in the form of a resting left ventricular ejection fraction of no more than 35 percent or a resting left ventricular ejection fraction of less than 45 percent with a left ventricular internal end-diastolic diameter of more than 2.9 cm per square meter of body-surface area or more than 6.5 cm on the basis of echocardiography.
Women were excluded if they were pregnant, nursing, or of childbearing age and not using an effective method of contraception. The following were also reasons for exclusion: an acute myocardial infarction, acute coronary syndrome, or stroke within the preceding three months; cardiac surgery or percutaneous coronary intervention within the preceding three months or the likelihood of a requirement for such procedures during the study period; the presence of clinically significant valvular heart disease, hypertrophic or restrictive cardiomyopathy, active myocarditis, or uncontrolled hypertension; a history of cardiac arrest or life-threatening arrhythmias within the preceding three months (unless they had been treated with an implantable defibrillator); treatment with parenteral inotropic agents within one month before randomization; a potential need for cardiac transplantation; the presence of symptomatic hypotension; the presence of an illness other than heart failure that was likely to result n methods in death within the study period; an inability to complete the quality-of-life questionnaire; and contraindications to the use of nitrate or hydralazine therapy.
randomization procedure
Randomization was performed centrally by Medifacts International, with stratification according to the use or nonuse of beta-blockers as background therapy. Blocks of 4 patients per stratum were used, with each site allowed to randomize up to 6 blocks of patients (24 patients) in the non-beta-blocker group and up to 10 blocks (40 patients) in the betablocker group.
Eligible patients were required to be receiving stable doses of therapy for heart failure and to have had a variation in body weight of less than 2.5 percent in the two weeks before randomization. At randomization, baseline evaluations included echocardiography, a metabolic profile, measurement of B-type natriuretic peptide and hemoglobin levels, and a quality-of-life questionnaire. After stratification according to the use or nonuse of beta-blockers as background therapy, patients were randomly assigned to receive a fixed-dose combination of isosorbide dinitrate plus hydralazine or to receive placebo, each in addition to background therapy. The initial dose was one tablet containing either placebo alone or 37.5 mg of hydralazine hydrochloride and 20 mg of isosorbide dinitrate three times daily. The dose was increased to two tablets three times daily, for a total daily dose of 225 mg of hydralazine hydrochloride and 120 mg of isosorbide dinitrate. An increase in the dose was dependent on the absence of drug-induced side effects as judged by the investigator. Patients were followed for up to 18 months, with assessment of the left ventricular ejection fraction, left ventricular internal diastolic dimension, left ventricular wall thickness, and level of B-type natriuretic peptide at 6 months and assessment of the quality of life every 3 months. Patients were interviewed by telephone monthly and returned for follow-up visits every three months.
outcome measures
The primary efficacy end point for the trial was a composite score made up of weighted values for death from any cause, a first hospitalization for heart failure during the 18-month follow-up period, and change in the quality of life at 6 months. The quality of life was assessed by means of the Minnesota Living with Heart Failure questionnaire, a 21-question self-administered instrument in which scores can range from 0 to 5 for each question, and higher scores indicate a poorer quality of life. 42 The composite scoring system is shown in Table 1 .
Secondary end points included individual components of the primary composite score, death from cardiovascular causes, the total number of hospitalizations for heart failure, the total number of hospitalizations for any reason, the total number of days of hospitalization, the overall quality of life throughout the trial, the number of unscheduled emergency room and office or clinic visits, the change in B-type natriuretic peptide level at six months, a newly recognized need for cardiac transplantation, and a change in the left ventricular ejection fraction, the left ventricular internal diastolic dimension, and the left ventricular wall thickness at six months. Data on patients who underwent cardiac transplantation during the trial were censored at the time of transplantation.
statistical analysis
Estimates of the sample size needed for the study to detect significant differences in the primary composite end point were based on data from V-HeFT I and II. Since the composite measure used in this trial had not been evaluated in previous trials, two interim analyses were prespecified in the protocol to permit an assessment of the adequacy of the sample size without knowledge of efficacy. The specific techniques for assessing the adequacy of the sample size were based on methods described by Cui et al. 43 The data and safety monitoring board met four times during the trial and conducted the prespecified interim analyses. The initial estimate that 800 patients (400 per group) were needed for the 
End Point Score
Death (at any time during the trial) ¡3
Survival to end of trial 0
First hospitalization for heart failure (adjudicated) ¡1
No hospitalization 0
Change in quality of life at 6 mo (or at last measurement if earlier than 6 mo)
Improvement by ≥10 units +2
Improvement by 5-9 units +1
Change by <5 units 0
Worsening by 5-9 units ¡1
Worsening by ≥10 units ¡2 The primary efficacy comparison included all participants who had undergone randomization (intention-to-treat analysis). When data were missing, the worst-case score for that component of the composite end point was used in the primary analysis. The composite end point was compared between the groups with the use of a two-sample t-test.
The three individual components of the composite end point -death from any cause, first hospitalization for heart failure, and a change in the quality of life -were examined separately in secondary analyses. For the analysis of death from any cause, we used standard Kaplan-Meier survival methods with the log-rank test. These analyses included all randomized patients. We compared the incidence rates of death and of a first hospitalization for heart failure between groups using Fisher's exact test. We compared the change in the quality of life between groups using a two-sample t-test for the difference in scores (on the basis of the data obtained at six months or, when unavailable, data from the threemonth assessment carried forward).
Additional descriptive statistics were estimated for patients' characteristics and reported as the mean (±SD) or the total number (and percentage). Adverse events were also compared between groups with the use of chi-square tests.
Randomization was initiated on June 12, 2001 , and the study was terminated on July 19, 2004 , on the recommendation of the independent data and safety monitoring board after 1050 of the planned 1100 patients had undergone randomization -518 to receive isosorbide dinitrate plus hydralazine and 532 to receive placebo. No patients were lost to follow-up.
The decision to stop the trial was based on the Lan-DeMets sequential-boundaries calculation. 44 The trial was halted owing to a significantly higher mortality rate in the placebo group than in the group given isosorbide dinitrate plus hydralazine. At the time the trial was halted, 54 patients had died in the placebo group (10.2 percent) and 32 patients had died in the combination-therapy group (6.2 percent). There was a significant 43 percent improvement in survival (hazard ratio, 0.57; P=0.01 by the log-rank test). The mean duration of follow-up was 10 months (range, 0 to 18). The Kaplan-Meier survival analysis (Fig. 1) demonstrates that survival differences emerged at approximately 180 days and widened progressively thereafter (P=0.01 by the logrank test).
The baseline clinical characteristics of the patients are shown in Table 2 . At the termination of the trial, the primary composite score was ¡0.1±1.9 in the group given isosorbide dinitrate plus hydralazine, as compared with ¡0.5±2.0 in the placebo group (P=0.01), thus demonstrating a significant beneficial effect of nitric oxide-enhancing therapy (Table 3 ). In addition to the reduction in the rate of death from any cause, the other individual components of the primary composite score were also significantly improved by treatment with isosorbide dinitrate and hydralazine (Table 3 ). The rate of first hospitalizations for heart failure was reduced by 33 percent, as compared with that in the placebo group (16.4 percent vs. 24.4 percent; 85 patients vs. 130 patients; P=0.001). The quality-of-life scores also improved more in the group given isosorbide dinitrate plus hydralazine than in the placebo group (¡5.6±20.6 vs. ¡2.7±21.2, P=0.02).
The composite end point was based on data on 1050 patients (the intention-to-treat population). A total of 742 patients filled out the quality-of-life questionnaire at six months. For all other patients, either an earlier post-baseline quality-of-life score was used or, if no such score was available, the patient received the worst possible score for the change in the quality of life (¡2) as part of the composite end point. The target dose was achieved in 68.0 percent of the patients in the group given isosorbide dinitrate plus hydralazine, as compared with 88.9 percent of the patients in the placebo group (P<0.001). The mean number of tablets per day was 3.8±2.5 in the group given isosorbide dinitrate plus hydralazine and 4.7±2.2 in the placebo group (P<0.001).
Combination therapy had a slight but significant blood-pressure-lowering effect at six months, decreasing systolic blood pressure by a mean of 1.9 mm Hg, as compared with an increase of 1.2 mm Hg in the placebo group (P=0.02), and decreasing diastolic blood pressure by a mean of 2.4 mm Hg, as compared with an increase of 0.8 mm Hg in the placebo group (P<0.001). There was no significant change in the heart rate between the two groups.
Adverse events are shown in Table 4 . Symptoms of headache and dizziness were significantly more frequent in the group given isosorbide dinitrate plus hydralazine, whereas exacerbations of congestive heart failure (both moderate and severe) were significantly more frequent in the placebo group.
We confirmed the findings in V-HeFT I of the efficacy and survival advantage of a combination of isosorbide dinitrate plus hydralazine added to standard background therapy in patients with moderate-tosevere heart failure. The trial population was limited to patients who identified themselves as black, a subgroup that had had a particularly favorable response to this therapy in retrospective analyses. 6, 38 The 43 percent reduction in the mortality rate in the group given isosorbide dinitrate plus hydralazine occurred among patients who were well treated with a background regimen of neurohormonalinhibitor drugs. Thus, the reduction in mortality is consistent with the existence of an alternative mechanism controlling the progression of heart failure. A similar reduction in mortality was previously reported among blacks with NYHA class II, III, or IV heart failure in V-HeFT I who were receiving only diuretics and digitalis rather than neurohormonalinhibiting agents. 6, 38 These results suggest that a fixed-dose combination of isosorbide dinitrate plus hydralazine may benefit patients in a manner that is independent of background therapy.
Growing evidence supports the concept that nitric oxide protects against myocardial and vascular discussion * Plus-minus values are means ±SD. NYHA denotes New York Heart Association, LVIDD left ventricular internal diastolic dimension, ACE angiotensin-converting enzyme, and ARB angiotensin-receptor blocker. Because of rounding, percentages may not total 100. † P=0.008 for the comparison with the placebo group. ‡ Data were obtained at screening. § P=0.01 for the comparison with the placebo group. ¶ P=0.002 for the comparison with the placebo group. The new england journal of medicine 2054 remodeling. 11, [22] [23] [24] [25] [26] [27] [45] [46] [47] The combination of isosorbide dinitrate and hydralazine may serve as a nitric oxide donor, with hydralazine conferring protection against the degradation of nitric oxide induced by oxidative stress. [48] [49] [50] [51] [52] Thus, data from A-HeFT support, but do not prove, the existence of a protective role of nitric oxide even in the presence of neurohormonal blockade. We used two strategies to demonstrate the efficacy of isosorbide dinitrate plus hydralazine as therapy for heart failure in a moderate-sized cohort. First, we designed the trial to include only patients self-identified as black, since previous data suggested that such patients had increased responsiveness to this therapy. 6,38 Second, we used a composite score, composed of weighted values for death from any cause, a first adjudicated hospitalization for heart failure, and change in the quality of life, as the primary end point. We hypothesized that including in the primary end point data relevant to all important outcomes of chronic disease would enhance the statistical power of the study to detect efficacy in a moderate-sized cohort. 53 The significant benefit of isosorbide dinitrate plus hydralazine demonstrated by the differences in the composite score (¡0.1±1.9, as compared with ¡0.5±2.0 in the placebo group; P=0.01) provides support for the use of such an end point in future trials.
Nitric oxide regulates cardiovascular processes including myocardial hypertrophy, remodeling, and substrate use, as well as vascular function, inflammation, and thrombosis. 11, [22] [23] [24] [25] [26] [27] [45] [46] [47] Substantial evidence exists that endothelial dysfunction and impaired bioavailability of nitric oxide occur in both ischemic and nonischemic models of heart failure and contribute to the pathophysiology of congestive heart failure. [12] [13] [14] [15] [16] [17] [18] [19] 21 Studies of murine models of heart failure -mice deficient in endothelial nitric oxide synthase and mice overexpressing nitric oxide synthase -have demonstrated the role of nitric oxide in preserving left ventricular performance, inhibiting myocardial remodeling, and improving survival. 23, 24, 27, 46 Nitric oxide has also been shown to regulate the use of myocardial substrate 47 and mitochondrial respiration. 25 In clinical models of heart failure, basal cardiac release of nitric oxide is decreased, 54 sensitivity to inhibition of nitric oxide synthase is increased, 55 nitric oxide-mediated processes are impaired, 12, 13, 18 and oxidative stress is increased. 14, 15, 17, 19, 20 Our choice of a study cohort of patients identifying themselves as black is based on observations of differences in prevalence, risk profiles, causation, disease severity, outcomes, and response to therapy between black patients and white patients with heart failure. [28] [29] [30] Retrospective analyses according to race in V-HeFT I, V-HeFT II, and the Studies of Left Ventricular Dysfunction have shown significant differences between blacks and whites in the response to pharmacotherapy for heart failure. 30, 38, 39 In a novel experimental system, Kalinowski et al. 37 found that, as compared with endothelial cells from healthy white women, endothelial cells from healthy black women had diminished bioavailability of nitric oxide as a result of increased oxidative stress. Data suggesting that endothelial function and bioavailability of nitric oxide may be less robust in blacks than in whites 32-37 lend credibility to the hypothesis that the balance of mechanisms leading to the progression of heart failure may vary with geographic origin. The combination of isosorbide dinitrate and hydralazine was used as a vasodilator in V-HeFT I because of its balanced effect on arteriolar dilation and venodilation. Once the physiologic role of nitric oxide was elucidated, it became apparent that isosorbide dinitrate exerts its vasodilatory effect by donating nitric oxide or forming related compounds. 48, 56 Concomitant administration of hydralazine prolongs the vasodilatory effects of isosorbide dinitrate in experimental and clinical models. 19,49-52 Munzel et al . 51 have shown that hydralazine is an effective antioxidant, inhibiting the generation of nitric oxide-inactivating reactive oxygen species by inhibiting vascular NADH and NADPH oxidases. Similarly, other antioxidants have been shown to reduce the mitochondrial production of reactive oxygen species. 57 Thus, hydralazine, by reducing oxidative stress, may enhance the effects of nitric oxide derived from nitric oxide donors as well as from endogenous sources. This study, however, does not establish that these mechanisms explain the clinical benefit of isosorbide dinitrate plus hydralazine in heart failure.
Our trial represents a departure from the recent approach to the design of cardiovascular trials. Rather than studying a large heterogeneous population, we examined a specific population in whom efficacy was more likely to be established. A heterogeneous population may have substantial variations in genetic and environmental factors that influence disease progression and the response to therapy. Since subgroups of the trial cohort are rarely large enough for statistical analyses of the heterogeneity of an effect, the standard thinking is that the overall response to therapy should be accepted as a mandate for the use of that therapy in all subgroups in the trial. Recent insights into mechanistic variability, however, lend credence to the concept that the average effects in heterogeneous populations may obscure therapeutic efficacy in some subgroups and the lack of such efficacy in others.
Our finding of the efficacy of isosorbide dinitrate plus hydralazine in black patients provides strong evidence that this therapy can slow the progression of heart failure. A future strategy would be to identify genotypic and phenotypic characteristics that would transcend racial or ethnic categories to identify a population with heart failure in which there is an increased likelihood of a favorable response to such therapy.
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